PEG-MGF: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store lyophilized powder at -20C for long-term storage or 2-8C short-term. Reconstituted solution should be stored at 2-8C and used within 2-3 weeks. Do not freeze reconstituted solution. Protect from light. PEG-MGF is significantly more stable than native MGF due to PEG protection.
Protocol Quick-Reference
Muscle recovery and tissue repair research
Dosing
Amount
200 mcg
Frequency
2-3 times per week
Duration
4-8 weeks
Administration
Route
SCSchedule
2-3 times per week
Timing
On non-training days or post-exercise; timing not firmly established
โ Rotate injection sites
Cycle
Duration
4-8 weeks
Repeatable
Yes
Preparation & Storage
Diluent: Bacteriostatic water
Storage: Store lyophilized powder at -20C for long-term storage or 2-8C short-term. Reconstituted solution should be stored at 2-8C and used within 2-3 weeks. Do not freeze reconstituted solution. Protect from light. PEG-MGF is significantly more stable than native MGF due to PEG protection.
โ๏ธ Suggested Bloodwork (6 tests)
IGF-1
When: Baseline
Why: Baseline growth factor levels (MGF signals through IGF-1 pathways)
CBC
When: Baseline
Why: General health baseline and platelet count
CMP with liver enzymes
When: Baseline
Why: Liver and kidney function baseline
Fasting glucose and HbA1c
When: Baseline
Why: Growth factors can affect glucose metabolism
IGF-1
When: 4 weeks
Why: Assess growth factor pathway stimulation
Fasting glucose
When: 4 weeks
Why: Monitor for glucose metabolism changes
๐ก Key Considerations
- โCommon dose range is 200-500 mcg per injection
- โContraindication: Avoid with known or suspected malignancy due to cell proliferative effects; not studied in pregnancy or nursing
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Muscle recovery research | 200 mcg | 2-3 times per week | 4-6 weeks | Subcutaneous injection. Extended half-life allows less frequent dosing than native MGF. No human clinical validation exists for any protocol. |
| Post-exercise recovery research | 200-500 mcg | 2-3 times per week (on non-training days) | 4-8 weeks | Some protocols suggest administration on non-training days to separate the PEG-MGF signal from the natural post-exercise MGF pulse. This timing rationale has not been validated. |
| Localized tissue repair research | 100-200 mcg | 2-3 times per week | 4 weeks | Subcutaneous injection near the target area. The extended half-life of PEG-MGF allows for systemic distribution even from distant sites. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Reconstitute lyophilized PEG-MGF powder with bacteriostatic water. For a typical 2 mg vial, add 1-2 mL of diluent. Gently swirl (do not shake) until dissolved. Solution should be clear and colorless. PEG-MGF is more stable than native MGF in reconstituted form. Use within 2-3 weeks when refrigerated.
Recommended Injection Sites
- โSubcutaneous (abdomen)
- โSubcutaneous (thigh)
- โSubcutaneous (upper arm)
- โSubcutaneous (near target area, for localized protocols)
๐งStorage Requirements
Store lyophilized powder at -20C for long-term storage or 2-8C short-term. Reconstituted solution should be stored at 2-8C and used within 2-3 weeks. Do not freeze reconstituted solution. Protect from light. PEG-MGF is significantly more stable than native MGF due to PEG protection.
Community Dosing Protocols
Compare these clinical doses with what 50+ community members report using.
Based on 50+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Research Dosing Disclaimer#
Dosing Overview#
PEG-MGF dosing differs fundamentally from native MGF dosing due to its extended half-life. While native MGF requires daily or more frequent administration due to its approximately 5-7 minute half-life, PEG-MGF's half-life of several hours allows for dosing 2-3 times per week, making it considerably more practical for research applications.
However, it is important to emphasize that no human pharmacokinetic studies have been conducted for PEG-MGF. All dosing information is extrapolated from preclinical MGF data, PEGylation pharmacology principles, and uncontrolled anecdotal observations. No dose-response relationship has been established, and the optimal dose for any biological endpoint in humans is unknown.
Preclinical Context#
Relationship to Native MGF Dosing#
PEG-MGF dosing cannot be directly derived from native MGF doses because PEGylation fundamentally changes the pharmacokinetic profile. The extended half-life means that a single dose of PEG-MGF provides sustained exposure over hours, compared to minutes of exposure from native MGF. This means that the total amount of biological signaling from a single PEG-MGF dose may exceed that from a single native MGF dose, even at the same microgram amount.
Additionally, PEG-MGF distributes systemically rather than acting locally, meaning that the peptide concentration at any given tissue is lower than would be achieved with a local native MGF injection of the same amount.
Preclinical MGF Studies as Reference#
The animal study doses for native MGF (0.5-5 mcg for intramuscular injection in mice; 10-50 mcg for local application in rabbit bone models) provide limited guidance for PEG-MGF dosing in humans. Allometric scaling between species is unreliable for PEGylated compounds because PEG metabolism, distribution, and clearance differ significantly between small animals and humans.
Administration Protocols#
Subcutaneous Injection#
PEG-MGF is typically administered by subcutaneous injection, which provides:
- Controlled absorption over minutes to hours
- Systemic distribution throughout the body
- Flexibility in injection site selection (unlike native MGF, which requires local injection)
- Simple administration technique with standard insulin syringes
The extended half-life eliminates the need for injection near the target tissue, although some protocols still suggest local administration for theoretical advantages.
Dosing Frequency#
The 2-3 times per week dosing frequency commonly described in anecdotal protocols is based on the assumption of a half-life in the range of hours. This frequency aims to maintain biologically relevant peptide concentrations while avoiding continuous exposure that could disrupt the natural balance between proliferative and differentiative signaling.
Timing Considerations#
Some protocols suggest specific timing relative to exercise:
- Non-training day administration: Based on the theory that endogenous MGF is produced during exercise, and exogenous PEG-MGF should be separated from this natural pulse to avoid receptor desensitization
- Post-training administration: Based on the theory that PEG-MGF should supplement the natural post-exercise MGF response
- Time-independent administration: Based on the view that PEG-MGF's sustained exposure makes timing irrelevant
None of these timing strategies has been validated in controlled studies.
Comparison with Native MGF Dosing#
| Parameter | Native MGF | PEG-MGF |
|---|---|---|
| Dose range | 100-200 mcg/day | 200-500 mcg per injection |
| Frequency | Daily | 2-3 times per week |
| Duration | 4-6 weeks | 4-8 weeks |
| Injection site | Near target tissue | Any subcutaneous site |
| Timing | Post-exercise (within 30 min) | Flexible |
| Administration window | Very narrow (rapid degradation) | Several hours |
| Total weekly dose | 700-1400 mcg | 400-1500 mcg |
Reconstitution Protocol#
Step-by-Step Instructions#
- Remove from freezer: Allow the lyophilized PEG-MGF vial to reach room temperature (15-20 minutes)
- Clean vial tops: Swab the rubber stoppers of both the PEG-MGF vial and bacteriostatic water with alcohol
- Draw diluent: Using a sterile syringe, draw 1-2 mL of bacteriostatic water
- Reconstitute: Insert the needle through the PEG-MGF vial stopper and direct the water against the glass wall, not directly onto the powder
- Dissolve: Gently swirl until the powder is completely dissolved. Do not shake vigorously
- Verify: Solution should be clear and colorless. Discard if cloudy or contains particulates
- Label: Record reconstitution date and concentration on the vial
Concentration Calculations#
| Vial Size | Diluent Volume | Concentration | 200 mcg Dose |
|---|---|---|---|
| 2 mg | 1 mL | 2000 mcg/mL | 0.10 mL (10 units) |
| 2 mg | 2 mL | 1000 mcg/mL | 0.20 mL (20 units) |
| 5 mg | 2 mL | 2500 mcg/mL | 0.08 mL (8 units) |
| 5 mg | 2.5 mL | 2000 mcg/mL | 0.10 mL (10 units) |
Injection Technique#
Subcutaneous Injection#
- Draw the calculated dose into a 29-31 gauge insulin syringe
- Select and clean the injection site with an alcohol swab
- Pinch a fold of skin at the injection site
- Insert the needle at a 45-degree angle
- Inject slowly over 5-10 seconds
- Release the skin fold and withdraw the needle
- Apply gentle pressure with a cotton swab
Injection Site Rotation#
Unlike native MGF (which is injected near the target tissue), PEG-MGF can be injected at standard subcutaneous sites. Rotate among abdomen, thigh, and upper arm to prevent injection site reactions and lipodystrophy.
Storage and Stability#
Lyophilized Powder#
PEG-MGF lyophilized powder is significantly more stable than native MGF:
- Long-term: -20C for up to 12 months
- Short-term: 2-8C for up to several months
- Room temperature: Avoid prolonged exposure
- Protection: Sealed vial, protected from light and moisture
Reconstituted Solution#
One of the practical advantages of PEG-MGF over native MGF is improved reconstituted stability:
- Storage: 2-8C (refrigerator)
- Duration: Up to 2-3 weeks (vs 24-48 hours for native MGF)
- Do not freeze: Freeze-thaw cycles denature the peptide
- Bacteriostatic water: Provides antimicrobial protection for multi-use vials
Evidence Gaps#
- No human pharmacokinetic or dose-finding studies have been conducted
- Optimal dosing frequency based on actual half-life data is unknown
- Dose-response relationship has not been characterized for any endpoint
- The minimum effective dose in humans is unknown
- Whether timing relative to exercise affects efficacy is untested
- Long-term effects of repeated PEG-MGF dosing are unknown
- Interaction with concurrent growth factor or growth hormone use on dosing requirements is unstudied
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About PEG-MGF
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.